Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have been assigned a consensus rating of “Buy” from the ten research firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $27.83.
A number of brokerages recently commented on DNLI. BTIG Research began coverage on shares of Denali Therapeutics in a research report on Friday, August 9th. They issued a “buy” rating and a $30.00 target price on the stock. ValuEngine lowered shares of Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 2nd. Nomura began coverage on shares of Denali Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 27th. Finally, Wedbush began coverage on shares of Denali Therapeutics in a report on Wednesday, September 25th. They issued a “neutral” rating and a $19.00 price target on the stock. They noted that the move was a valuation call.
NASDAQ:DNLI traded up $0.24 during trading hours on Friday, reaching $15.44. The company’s stock had a trading volume of 5,461 shares, compared to its average volume of 374,113. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -39.67 and a beta of 2.15. The firm has a 50-day simple moving average of $17.38 and a 200-day simple moving average of $20.51. Denali Therapeutics has a 1 year low of $13.78 and a 1 year high of $28.86. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.66 and a current ratio of 10.65.
In other news, COO Alexander O. Schuth sold 7,500 shares of Denali Therapeutics stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $18.81, for a total transaction of $141,075.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ryan J. Watts sold 8,581 shares of Denali Therapeutics stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $18.05, for a total transaction of $154,887.05. Following the sale, the chief executive officer now directly owns 12,505 shares in the company, valued at approximately $225,715.25. The disclosure for this sale can be found here. In the last three months, insiders sold 23,581 shares of company stock worth $432,162. Insiders own 21.20% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in DNLI. Baillie Gifford & Co. boosted its stake in shares of Denali Therapeutics by 18.3% during the 2nd quarter. Baillie Gifford & Co. now owns 7,407,229 shares of the company’s stock valued at $153,773,000 after purchasing an additional 1,145,003 shares in the last quarter. Pictet Asset Management Ltd. bought a new stake in shares of Denali Therapeutics during the 2nd quarter valued at about $15,349,000. BlackRock Inc. boosted its stake in shares of Denali Therapeutics by 13.3% during the 2nd quarter. BlackRock Inc. now owns 5,154,097 shares of the company’s stock valued at $106,999,000 after purchasing an additional 604,766 shares in the last quarter. Wasatch Advisors Inc. boosted its stake in shares of Denali Therapeutics by 21.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 996,147 shares of the company’s stock valued at $20,680,000 after purchasing an additional 175,243 shares in the last quarter. Finally, Nuveen Asset Management LLC bought a new stake in shares of Denali Therapeutics during the 2nd quarter valued at about $3,632,000. 73.91% of the stock is currently owned by hedge funds and other institutional investors.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Featured Story: What is operating income?
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.